本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

阿斯利康

75.97
-1.5300-1.97%
成交量:486.83萬
成交額:3.72億
市值:2,355.99億
市盈率:33.76
高:76.97
開:76.11
低:75.48
收:77.50
資料載入中...

公司資料

公司名字:
阿斯利康
交易所:
NASDAQ
成立時間:
1992
員工人數:
94300
公司地址:
1 Francis Crick Avenue,Cambridge Biomedical Campus,Cambridge,Cambridgeshire,United Kingdom
郵編:
CB2 0AA
傳真:
44 1223 352 858
簡介:
阿斯利康股份有限公司於1992年6月17日根據1985年《公司法》在英格蘭和威爾士註冊成立。該公司是在1993年將Imperial化學工業公司的製藥、農化和特種化學品業務分拆時成立的。1999年,公司出售了特種化學品業務。同樣在1999年,該公司與瑞典Astra公司合併。2000年,該公司將農化業務分拆,並將其與諾華公司的同類業務合併,成立了一家新的公司Syngenta AG。2007年,集團收購了位於美國的生物製劑和疫苗企業MedImmune。2021年,集團收購了位於美國的罕見病企業Alexion。

董事

名稱
職位
Pascal Soriot
Executive Director and Chief Executive Officer
Aradhana Sarin
Executive Director and Chief Financial Officer
Diana Layfield
Non-Executive Director
Euan Ashley
Non-Executive Director
Karen Knudsen
Non-Executive Director
Leif Johansson
Non-Executive Chair of the Board
Marcus Wallenberg
Non-Executive Director
Michel Demare
Non-Executive Director
Nazneen Rahman
Non-Executive Director
Philip Broadley
Non-Executive Director and Non-Executive Director and Chair of Lancashire Holdings Limited
Sheri McCoy
Non-Executive Director
Tony Mok
Non-Executive Director

股東

名稱
職位
Marc Dunoyer
Chief Executive Officer, Alexion and Chief Strategy Officer, AstraZeneca
Pascal Soriot
Executive Director and Chief Executive Officer
Aradhana Sarin
Executive Director and Chief Financial Officer
David Fredrickson
Executive Vice-President, Oncology Business Unit
Iskra Reic
Executive Vice-President, Vaccines, Executive Vice President and Immune Therapies
Jeff Pott
Chief Compliance Officer, Chief Human Resources Officer and General Counsel
Katarina Ageborg
Executive Vice-President, Sustainability and Chief Compliance Officer, President of AstraZeneca AB Sweden
Leon Wang
Executive Vice-President, International and China President
Menelas Pangalos
Executive Vice-President, BioPharmaceuticals R&D
Pam Cheng
Executive Vice-President, Operations, Information Technology and Sustainability
Ruud Dobber
Executive Vice-President and President, BioPharma ceuticals Business Unit
Susan Galbraith
Executive Vice-President, Oncology R&D